Detalhe da pesquisa
1.
Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa.
Cell
; 186(23): 5098-5113.e19, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37918395
2.
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.
Cell
; 178(3): 699-713.e19, 2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31280963
3.
Sensitizing protective tumor microenvironments to antibody-mediated therapy.
Cell
; 156(3): 590-602, 2014 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24485462
4.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(19): 1739-1754, 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163621
5.
Targeting the tumor microenvironment for treating double refractory chronic lymphocytic leukemia.
Blood
; 2024 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38776510
6.
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
Blood
; 143(6): 522-534, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946299
7.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620072
8.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620092
9.
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.
Blood
; 141(12): 1425-1441, 2023 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36179280
10.
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Blood
; 141(5): 519-528, 2023 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36084320
11.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363867
12.
Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.
Blood
; 142(1): 44-61, 2023 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37023372
13.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood
; 142(5): 446-459, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37172204
14.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 25(6): 744-759, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38821083
15.
COVID-19 in patients with hematologic malignancy.
Blood
; 140(3): 236-252, 2022 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35544585
16.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood
; 139(9): 1318-1329, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35108374
17.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood
; 139(2): 177-187, 2022 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34758069
18.
Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies.
Blood
; 139(25): 3617-3629, 2022 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35344582
19.
A diagnostic challenge-First case of chronic lymphatic leukemia-associated necrotizing sweet syndrome.
Eur J Haematol
; 112(4): 650-653, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38105522
20.
Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
Eur J Haematol
; 112(6): 984-987, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38316549